New South Wales is home to a strong, diverse, and world-recognised ribonucleic acid (RNA) research and development (R&D) ecosystem supported by a leading clinical trials system.
The NSW Government is currently delivering a new RNA Pilot Manufacturing Facility to provide necessary infrastructure to support the development of RNA drugs and vaccines in NSW. Investment in complementary R&D is critical to translate research strengths into a sustainable commercial pipeline of RNA therapeutics and products for trialling at the RNA Pilot Manufacturing Facility.
The NSW Government has allocated funding of $119 million over 10 years to RNA R&D to further develop the NSW RNA ecosystem and to support a pipeline of projects for piloting at the facility.
On Friday 23 December 2022, the NSW Government opened registrations of interest for the establishment of an RNA Investment Fund. Registrations of interest are now closed.
Funding for the RNA Pilot Manufacturing Facility and the RNA Investment Fund has been confirmed in the 2023 NSW Budget in line with the original commitment.